Background and Aims: The burden of inflammatory bowel disease [IBD] in health care is high. We conducted research on the temporal changes in the incidence of paediatric IBD [PIBD] using nationwide registry-based data in Finland. Methods: All PIBD cases diagnosed at less than 20 years of age during 1987-2014 [in total, 5415 patients] were retrieved from a database documenting reimbursements for drug costs. Incidence rates were calculated by dividing the number of annual new PIBD cases by the size of the paediatric population at risk during each calendar year. Temporal trends in the incidences of PIBD and its subtypes, ulcerative colitis [UC] and Crohn's disease [CD], were estimated using Poisson regression analyses. Results: The mean annual incidence of PIBD increased from 7/100 000 for the years 1987-1990 to 23/100 000 for the years 2011-2014. The average rate of increase was 4.1% (95% confidence interval [CI]: 3.6-4.5) per annum. In the period 2000-2014, the increase rate in the annual incidence of UC [3.8%; 95% CI: 2.7-5.0], was steeper than for CD [2.5%; 95% CI: 1.0-3.8]. The most pronounced increase occurred in UC among adolescents aged [16] [17] [18] [19] . For children less than 10 years of age, the rate of change remained low. Approximately 0.17% of the birth cohort for the years 1999-2000 was diagnosed with PIBD by the age of 14 years.
Introduction
Inflammatory bowel diseases [IBD] , namely ulcerative colitis [UC], Crohn's disease [CD] and unclassified colitis [IBD-U], have dramatically increased in incidence in Western countries during the past couple of decades. It is obvious that environmental factors play a role, but so far no definite clues for the observed increases in incidences have been discovered. Disease pathogenesis involves genetic predisposition, the intestinal microbiome and dysregulated immune responses. 1, 2 Paediatric IBD [PIBD] affects children of all ages, but it is more common around the time of puberty. In most countries, CD is the most predominant subtype of PIBD. 3, 4 In Finland, UC is predominant in both adult and paediatric age groups, 5, 6 which is in line with reports from, for example, Italy, Denmark, Iceland and Poland. [7] [8] [9] [10] Most reports on the epidemiology of PIBD highlight a continuous rise in the incidence of the disease, 8, 9, [11] [12] [13] [14] [15] especially in school-aged children. 11, 12 However, some reports describe a more stable state, [16] [17] [18] whereas several even note a decreasing trend. 19, 20 We observed a continuous increase in the incidence of PIBD in Finland up to the year 2003, when the incidence reached the level of 15 per every 100 000 among patients less than 18 years of age. 5 Another study from Finland confirmed an ongoing increase in the incidence of UC between 2000 and 2007, reaching an incidence rate of 25 per every 100 000 people in a patient group covering all ages. 6 Interestingly, the incidence of CD seemed to be fairly stable. 6 Thus, the existing studies regarding current trends in the incidences of PIBD do not all agree with one another and may reflect geographical differences.
We used the opportunity to study nationwide long-term data from well-defined national registries of Finland as a means of thoroughly assessing temporal changes in the incidences of PIBD and its subtypes among children less than 20 years of age during a 28-year period up to the year 2014. We also assessed whether there were any age-related differences in the temporal changes of PIBD.
Materials and Methods

Data sources and study population
In this retrospective cohort study, the data were collected from two national registries: patient information from the Special Reimbursement Registry, maintained by the Social Insurance Institution of Finland [SII] ; and census data from the Population Registry, maintained by the Population Registry Centre Finland. The excellent coverage of these registries has been described elsewhere. [21] [22] [23] The Finnish Population Information System contains basic information on both Finnish and foreign citizens residing permanently in Finland, linked by a unique personal identity code. More than 98% of the Finnish population [5.47 million in 2014] is of Caucasian origin. 24 The target population consisted of children less than 20 years of age [1987 N = 1.27 million and 2014 N = 1.20 million]. Finland is located in Northern Europe.
Finland has a National Health Insurance Scheme that covers all residents. The costs for drugs prescribed by a physician for treating an illness are reimbursed by the SII. At present, the basic refund rate is 35% of the drug's cost. For certain severe chronic diseases, including IBD, where defined drug treatments are essential, the patients can be entitled to a higher refund of up to 100%.
For 
Identification of IBD patients
To be eligible for IBD drug reimbursement, a patient must verify the diagnosis with a medical certificate from the treating physician, primarily a specialist in gastroenterology, paediatrics or digestive surgery. The certificate should include all diagnostic procedures along with a description of the symptoms and the results of the proper diagnostic tests. For the classification of IBD subtypes, the criteria include endoscopy and, in most cases, histological verification. 22, 25 A medical examiner at the local SII office checks whether or not the special refund should be applied before the benefit can be granted. During the period 2005-2012, more than 98% of the applications written for IBD were accepted by the SII; rejections are exceptional for children. The entire administrative process from certificate writing to the final decision by the SII generally takes only a couple of weeks, and the benefit is granted retrospectively starting from the date when the certificate was issued. Since 1986, the SII has recorded all patients entitled to a special refund for IBD in a nationwide registry. Since 2000, the ICD-10 diagnosis codes K50 and K51 have been included in the registry to separately identify patients with CD and patients with UC [with the latter including IBDU]. As a general rule, special reimbursements for IBD are granted indefinitely; however, the SII may at first grant a temporary reimbursement for 1-3 years if the subtype is uncertain. Thus, the registry may include several entries for some patients diagnosed with different IBD subtypes, but these are read as one person when the data are retrieved from the registry [see below]. The excellent coverage and validity of the registry was previously confirmed in a randomly selected sample of paediatric IBD patients. 5 Also, we ensured that the cases were truly incident by checking back whole IBD registry data for all children starting from the year 1986 [starting time of the IBD registry].
For the present study, we retrieved from the special reimbursement registry information on all children under 20 years of age who had been granted a special refund for IBD between January 1, 1987 and December 31, 2014. The dates [month and year] when the decision regarding the special refund took effect were used as a proxy indicator for the date of diagnosis. For those particular patients entitled to several reimbursements due to a change in diagnosis, only the first date and the final diagnosis were included.
The 
Statistical methods
The annual incidence rates per 100 000 at-risk children were calculated by dividing the number of newly diagnosed PIBD cases by the total number of paediatric population [0-19 years of age] during each calendar year between 1987 and 2014. Poisson regression models with the number of new cases as the response variable and log e at-risk person-years as the offset were used to calculate the estimates with 95% confidence intervals [95% CI] for the incidence rates. Based on the age-specific incidences of PIBD [ Figure 1 ], the age at diagnosis was categorized into three groups: 0-9, 10-15 and 16-19 years of age [childhood, early adolescence and late adolescence]. To check the linear behaviour of the annual incidences by age group, the observation time for PIBD in the years 1987-2014 was split into seven 4-year subperiods [Supplementary Tables 2 and 3 ]. We did not perform agesex standardization as during this observation period of 28 years the size of the birth cohorts remained stable, e.g. 58 180 in 1987 and 57 562 in 2014. Of these, 51% were boys throughout the study period. Thus, the variation in absolute numbers is low.
The temporal changes in the incidence of PIBD and PIBD subtypes were estimated using Poisson regression models to detect the following: [i] the magnitude of change in the incidence rates during the overall follow-up period; [ii] the trends of change in the total incidence rate during all of the observation years; and [iii] the variation in the change of incidence rates between age groups at the onset of IBD during the follow-up period. The magnitude of change in incidence rates during the total 28-year follow-up period for PIBD and 15-year followup period for UC and CD was quantified by calculating periodical incidence rate ratios [IRR] with a 95% CI between the first and last periods. All of the models included the age group at the onset of PIBD, gender and their significant pairwise interactions as predictors. The shape of the profiles was first checked using models that included the year of diagnosis divided into different subperiods and modelled as a categorical predictor [data not shown]. Whereas the rate of change was steady throughout the study period, the trends noted during the observation years were estimated based on the slopes of the incidence rates in the models and by including the year of IBD diagnosis as a continuous predictor. The confidence intervals used in multiple comparisons were Bonferroni-corrected to control for multiplicity.
Cumulative incidences of UC and CD in children and adolescents up to 14 years of age [until December 31, 2014] were calculated as percentages using a 2-year cohort of all live-born infants in Finland between January 1, 1999 and December 31, 2000 [boys N = 58 650; girls N = 55 666] as the at-risk population. Statistical analyses were done using the procedure GENMOD provided in the SAS 9.4 software [SAS Institute, Cary, NC, USA].
Ethical considerations
The data permit was admitted by the SII [diary no. 15/522/2013]. In accordance with Finnish legislation, no approval by an ethical committee nor informed consent is required for registry-based studies done without contacting the study subjects.
Results
Long-term changes in the incidence of PIBD in the years 1987-2014
The age-specific incidences of PIBD during the years 1987-2014 are shown in Figure 1 . During the 28-year observation period, the nationwide mean annual incidence of PIBD in Finland tripled from 7/100 000 in [1987] [1988] [1989] [1990] During 15-year observation period 2000-2014, the increase rate in the annual incidence of UC averaged 3.8% [95% CI: 2.7-50; Table 1 ]. This temporal trend in the incidence rate differed significantly among the three age groups [p = 0.035 for year of diagnosis × age group interaction]: among children less than10 years of age, the rate of change remained low, on average 0.9% per annum. Among older children, the increases in the annual incidences of UC were highly significant: 3.3% and 4.8% [ Table 1 ].
Temporal changes in the incidence of CD in the years 2000-2014
The mean annual incidence of CD increased from 6/100 000 in 2000-2004 to 8/100 000 in 2010-2014 [Supplementary Table 3 ]. The magnitude of increase in the incidences between the last and first 5-year periods was significant, with the sub-periodic IRR being 1.3 [95% CI: 1.0-1.6; p = 0.049]. However, this change in the incidences between the extreme periods did not differ among the three age groups [p = 0.681 for period × age group interaction; Figure 2b ].
During 15-year observation period 2000-2014, the increase in the annual incidence rate of CD averaged 2.5% [95% CI: 1.1-3.9; Table 1 ]. This trend did not differ among the different age groups [p = 0.522 for year of diagnosis × age group interaction; Table 1 ].
Cumulative incidences of PIBD subtypes in children and adolescents up to 14 years of age
In the birth cohort for the years 1999-2000, the estimated number of age-related cumulative incidences of PIBD increased gradually [ Figure 3 ]. By the age of 7 years, approximately 0.022% of the 
Discussion
In this nationwide report on the incidence of PIBD in Finland, we show that the number of children diagnosed with IBD is continuously increasing. This increase is most prominent during adolescence. Among adolescents 16 to 19 years of age, the mean annual incidence of UC reached 40, whereas the rate of incidence for CD reached 17 per 100 000 persons between the years 2010 and 2014. In contrast to the situation with older children, the incidence rate seems to have plateaued among those 0 to 9 years of age. Nearly 0.2% of infants in the most recent birth cohort with complete 14 years of followup, those born between 1999 and 2000, were diagnosed with PIBD. The observed and ongoing rise in IBD among adolescent patients challenges the identification of possible environmental factors with respect to being at risk for contracting the disease. The highest incidence rates of PIBD have been reported among children in Western countries, especially in Canada and Northern Europe. 3, 4 During the observation period of 28 years, we identified 5415 PIBD patients. The observed incidence rates of PIBD [23/100 000 among those less than 20 years of age and 13/100 000 among those less than 16 years of age during 2011-2014], and in particular the incidence of UC [8/100 000 among those less than 16 years of age], are comparable to figures reported from Scandinavia, 18 and they are among the highest incidences of PIBD published so far. Finland is one of the few countries that reportedly shows a predominance of UC over CD. 3, 4 The reported frequency of IBD-U is less than 10% among paediatric IBD patients in Finland. 26 Thus, this subtype of IBD diagnoses does not explain the high proportion of UC patients, these two subtypes grouped together in the analyses. Accordingly, we observed a steeper increase in the incidence of UC than CD. Among the 2-year birth cohort for the years 1999-2000 with a full 14-year follow-up, the cumulative incidence of both UC and CD was parallel among boys, whereas among girls the cumulative incidence of UC was more than two times higher than for CD, which is high compared with reports from other European countries [e.g. a recent report from Hungary 27 and for a review, see Molodecky 2012 4 ]. This is in line with the detected difference in the incidence of CD between boys and girls during the total follow-up period, with the levels for boys being 43% and 83% higher than for girls in age groups 0-9 years and 10-15 years, respectively. It was not, however, possible to study possible changes in the phenotypes because the registries do not include such data. In a recent genetic study, the largest such study to date, Cleynen et al. [2015] 28 reported on the associations between genotypes and phenotypes and suggested intrinsic disease aspects as major drivers of disease behaviour, but they did not touch on the epidemiology of the disease.
With respect to the incidence of paediatric type 1 diabetes, Finland is among the leading countries, with an annual incidence of approximately 64 per 100 000 in 2005. 29 Finland experienced a rapid increase in the incidence of paediatric type 1 diabetes in the 1990s, Another Finnish study on adult IBD 33 suggested that the observed north-south gradient in the incidence figures reported in, for example, Finland, Scotland 34 and France, 35 might be explained by the fact that persons in the northern parts of those countries exhibit somewhat lower levels of vitamin D. However, the reported differences in vitamin D levels in adults in different geographical areas of Finland proved to be marginal. 33 Furthermore, the observed increases in the intake of vitamin D among children in Finland suggest that vitamin D is not a key player in the observed increases in the incidences of PIBD. In line with this finding, vitamin D levels showed no association with β-cell autoimmunity in persons with type 1 diabetes. 36 Also, the association between vitamin D and other autoimmune diseases has been less clear. 31, 37 Thus, it is possible that other dietary factors play a more important role. According to follow-up studies, dietary habits and vitamin intake levels have changed among adolescents in Finland, but whether this is reflected in, for example, proinflammatory changes in gut microbiome, warrants more thorough research. 38 The risk of IBD has been linked to more than 160 susceptibility genes 39 and as yet unidentified environmental factors. The gut microbiome is associated with both risk and protective factors in autoimmune diseases. Two main hypotheses have been proposed to explain these effects: the hygiene hypothesis suggests that microbial exposures during early childhood stimulate immuno-regulatory mechanisms, which control autoimmune reactions [analogy with allergy]; the triggering hypothesis suggests that specific microbes damage cells, resulting in chronic inflammation. Recently, one study has suggested that bacteriophages are candidates for triggers. 40 A fascinating study on the epidemiology of allergic diseases demonstrated a marked difference in the commensal flora of skin between people living in Finland and in eastern Karelia in Russia, who shared similar genotypes, the observed bacteriome being associated with the biotope of the environment. 41 Precise data from PIBD incidences in eastern Karelia are lacking, but IBD is seemingly quite rare [M. Knip, personal communication] . The largest European study to date focusing on the East-West gradient in IBD epidemiology reported significantly lower incidences of IBD in Eastern Europe. 42 The incidence of early onset PIBD [among 0-9 year olds] increased between 1999 and 2008 in Ontario, Canada, but the change in the incidence was less among adolescents. 43 This contrasts with our findings and with less comprehensive reports from North America 11 and Scotland, 12 which found no increase in early-onset PIBD among the very young, among whom genetic factors are likely to play an important role in the risk of the IBD. In our population of children less than 5 years of age [very early-onset IBD], there was also no significant increase in temporal trends in incidence [data not shown]. The Canadian study cohort covered children born in early 2000 who had follow-up health assessments until the year 2008; however, it was not possible to estimate the onset of IBD for that particular cohort. Here, we observed an increase in the incidence of PIBD since early 2000 of between 40% and 60% for adolescents with UC and between 20% and 35% for adolescents with CD compared with the most recent years [2010] [2011] [2012] [2013] [2014] , with a mean annual increase of between 3% and 5% [but with age-dependent variability].
Our data are consistent, but still researchers should use caution when comparing the rates from the late 1980s with the more recent ones. Diagnostic techniques, including small bowel imaging, have improved and screening for PIBD is likely to be done more often because awareness of the disease is more widespread among physicians and the general population. During the Past decade, however, there have been no major changes in the screening of the disease in our country; for instance, faecal calprotectin measurements have been available in routine care in Finland since early 2000. 44 Disappointingly, a recent study on environmental risk factors did not identify any clear clues based on place of residence, proximity to paper mills or contaminants in the tap water that would explain the high rate of PIBD in Finland. 45 The strength of our study is the availability of comprehensive, nationwide patient data since 1986 based on written certificates listing the diagnostic criteria for IBD. 5, 26 Since 2000, the diagnostic subtypes, i.e. UC and CD, have been included in this registry data. All Finnish citizens are entitled to special reimbursements for the drug costs related to certain severe chronic diseases, including IBD. This benefit must specifically be applied for and the entitlement decisions are included in the registry data. As these entitlements are not dependent on socioeconomic status or place of residence within the country, most patients apply for a special reimbursement that covers not only systemic medication but also locally active therapies, such as enemas. The coverage of the registries is excellent, as has previously been discussed in more detail. 5, 22, 23 The SII grants the reimbursements and has not changed its criteria between 1987 and 2014.
Taken together, this dataset has provided evidence that between the years 2000 and 2014, a significant increase occurred in the incidence of UC among children over the age of 9 years and in the incidence of CD among children aged 10-15 years. However, the changes were lesser and non-significant among children under 10 years of age. These findings suggest that different causal factors for PIBD may exist in prepubertal and pubertal patients.
Funding
The work was supported by the Finnish Foundation for Paediatric Research [grant not numbered], by the Helsinki University Hospital Research Fund [grant number TYH2013321] and by the Sigrid Jusélius Foundation [grant not numbered]. The foundations providing grants had no role in the study's design nor in how we collected, analysed and interpreted the data, wrote the report or decided on how to submit the paper.
